{
  "Country": "PO",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NDRP) with KRAS G12C mutation after at least one previous line of therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR)"
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NDRP) with KRAS G12C mutation after at least one previous line of therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nintedanib in combination with Docetaxel",
      "Outcomes": "Progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR)"
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NDRP) with KRAS G12C mutation after at least one previous line of therapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pemetrexed",
      "Outcomes": "Progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR)"
    },
    {
      "Population": "Immunotherapy-na√Øve patients with advanced non-small cell lung cancer (NDRP)",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nivolumab or Atezolizumab",
      "Outcomes": "Overall survival, quality of life measures"
    }
  ]
}